
Journal of Medicinal Chemistry p. 1084 - 1104 (2020)
Update date:2022-08-15
Topics:
Kurasawa, Osamu
Miyazaki, Tohru
Homma, Misaki
Oguro, Yuya
Imada, Takashi
Uchiyama, Noriko
Iwai, Kenichi
Yamamoto, Yukiko
Ohori, Momoko
Hara, Hideto
Sugimoto, Hiroshi
Iwata, Kentaro
Skene, Robert
Hoffman, Isaac
Ohashi, Akihiro
Nomura, Toshiyuki
Cho, Nobuo
In our pursuit of developing a novel, potent, and selective cell division cycle 7 (Cdc7) inhibitor, we optimized the previously reported thieno[3,2-d]pyrimidinone analogue I showing time-dependent Cdc7 kinase inhibition and slow dissociation kinetics. These medicinal chemistry efforts led to the identification of compound 3d, which exhibited potent cellular activity, excellent kinase selectivity, and antitumor efficacy in a COLO205 xenograft mouse model. However, the issue of formaldehyde adduct formation emerged during a detailed study of 3d, which was deemed an obstacle to further development. A structure-based approach to circumvent the adduct formation culminated in the discovery of compound 11b (TAK-931) possessing a quinuclidine moiety as a preclinical candidate. In this paper, the design, synthesis, and biological evaluation of this series of compounds will be presented.
View More
website:http://www.np-chem.com
Contact:0086-25-52346877
Address:199, Jian Ye Road, Nanjing, China
Suzhou Lixin Pharmaceutical Co., Ltd.
Contact:86-512-88169812
Address:21 Tangxi Road, Suzhou New District, Suzhou 215151
Shandong Xingshun New Material Co., Ltd.
website:http://www.sd-xingshun.com
Contact:+86-519-86461196
Address:Middle of Luhua East Road, Dingtao District
Contact:+86 18616952870
Address:Area
Jiangsu Jiuri Chemical Co.,Ltd.
Contact:+86-519-82118868
Address:Tianwang Town, Jurong City, Jiangsu Province, China
Doi:10.1246/bcsj.62.3691
(1989)Doi:10.1007/BF00912610
(1974)Doi:10.1016/S0040-4020(01)91019-1
(1991)Doi:10.1021/acs.orglett.7b04042
(2018)Doi:10.1021/jacs.9b11601
(2019)Doi:10.1002/jlac.197419740208
(1974)